Patents by Inventor Michael A. Rudnicki

Michael A. Rudnicki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240238441
    Abstract: The present invention is based on the surprising finding that Wnt7a, and other Wnt family members, are trafficked to extracellular vesicles (EVs) via interactions with coatomer proteins. Extracellular vesicle signal peptides (ESPs), each comprising at least one key Coatomer binding motif (CBM), are described, and these mediate EV trafficking of Wnt family members. The ESPs may be used to target other proteins for display on EVs. Herein is described an EV comprising: COPI, and a recombinant EV-directed polypeptide comprising: a cargo polypeptide, and an ESP comprising a CBM, wherein the cargo polypeptide is tethered to an external surface of the EV via the coatomer binding motif. Also described are recombinant EV-directed polypeptides comprising an ESP and a cargo. Additionally described are recombinant skeletal muscle-targeted EVs comprising a pay load polypeptide; and recombinant Wnts having mutated CBM or ESPs, which are less trafficked to EVs for production/recovery of free Wnts.
    Type: Application
    Filed: May 3, 2022
    Publication date: July 18, 2024
    Inventors: Michael A. RUDNICKI, Uxia GURRIARAN-RODRIGUEZ, David Alexander DATZKIW
  • Publication number: 20230114123
    Abstract: The present disclosure provides a method for stimulating asymmetric division of at least some satellite stem cells in a patient suffering from a disease or disorder characterized by satellite cells having an inability, or a reduced ability, to assemble a functional dystrophin-associated glycoprotein complex (DGC) that results in an inability, or reduced ability, to establish cell polarity. The method includes administering to the patient a sufficient amount of an epidermal growth factor receptor (EGFR) pathway activator to stimulate asymmetric division of at least some satellite stem cells.
    Type: Application
    Filed: October 6, 2022
    Publication date: April 13, 2023
    Applicant: Ottawa Hospital Research Institute
    Inventors: Michael A. Rudnicki, Yu Xin Wang
  • Patent number: 10828346
    Abstract: There are provided compositions and methods for modulating stem cell division decisions, in particular, division symmetry. It has been demonstrated that wnt7a acts through frizzled-7 receptor expressed on the surface of adult stem cells, e.g. satellite stem cells, to activate the planar cell polarity (PCP) pathway, thereby promoting symmetrical expansion of stem cells. The compositions and methods of the invention are useful, for example, in modulating stem cell division symmetry in vitro and in vivo, in replenishing and expanding the stem cell pool, and in promoting the formation, maintenance, repair and regeneration of tissue.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: November 10, 2020
    Assignee: Ottawa Hospital Research Institute
    Inventors: Michael A. Rudnicki, Fabien Le Grand
  • Publication number: 20200038485
    Abstract: The present disclosure provides a method for stimulating asymmetric division of at least some satellite stem cells in a patient suffering from a disease or disorder characterized by satellite cells having an inability, or a reduced ability, to assemble a functional dystrophin-associated glycoprotein complex (DGC) that results in an inability, or reduced ability, to establish cell polarity. The method includes administering to the patient a sufficient amount of an epidermal growth factor receptor (EGFR) pathway activator to stimulate asymmetric division of at least some satellite stem cells.
    Type: Application
    Filed: April 17, 2018
    Publication date: February 6, 2020
    Inventors: Michael A. Rudnicki, Xin Yu Wang
  • Publication number: 20180360913
    Abstract: There are provided compositions and methods for modulating stem cell division decisions, in particular, division symmetry. It has been demonstrated that wnt7a acts through frizzled-7 receptor expressed on the surface of adult stem cells, e.g. satellite stem cells, to activate the planar cell polarity (PCP) pathway, thereby promoting symmetrical expansion of stem cells. The compositions and methods of the invention are useful, for example, in modulating stem cell division symmetry in vitro and in vivo, in replenishing and expanding the stem cell pool, and in promoting the formation, maintenance, repair and regeneration of tissue.
    Type: Application
    Filed: August 10, 2018
    Publication date: December 20, 2018
    Applicant: OTTAWA HOSPITAL RESEARCH INSTITUTE
    Inventors: Michael A. Rudnicki, Fabien LE GRAND
  • Patent number: 10071138
    Abstract: There are provided compositions and methods for modulating stem cell division decisions, in particular, division symmetry. It has been demonstrated that wnt7a acts through frizzled-7 receptor expressed on the surface of adult stem cells, e.g. satellite stem cells, to activate the planar cell polarity (PCP) pathway, thereby promoting symmetrical expansion of stem cells. The compositions and methods of the invention are useful, for example, in modulating stem cell division symmetry in vitro and in vivo, in replenishing and expanding the stem cell pool, and in promoting the formation, maintenance, repair and regeneration of tissue.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: September 11, 2018
    Assignee: Ottawa Hospital Research Institute
    Inventors: Michael A. Rudnicki, Fabien Le Grand
  • Patent number: 9732130
    Abstract: There are provided compositions and methods for modulating stem cell division, in particular, division symmetry. It has been demonstrated that Wnt7a polypeptide fragments promoting symmetrical expansion of stem cells. The compositions and methods of the invention are useful, for example, in modulating stem cell division symmetry in vitro, ex vivo, and in vivo, in replenishing and expanding the stem cell pool, and in promoting the formation, maintenance, repair and regeneration of tissue.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: August 15, 2017
    Assignee: Ottawa Hospital Research Institute
    Inventors: Michael A. Rudnicki, Conrad Florian Bentzinger, Radoslav Zinoviev
  • Publication number: 20170087188
    Abstract: The invention provides cell therapy compositions and associated methods. In particular embodiments, improved therapeutic cells and improved cell-based gene therapies for promoting cell or tissue formation, regeneration, repair or maintenance in a subject in need thereof are provided.
    Type: Application
    Filed: March 27, 2015
    Publication date: March 30, 2017
    Inventors: Michael A. RUDNICKI, Conrad Florian BENTZINGER
  • Publication number: 20170042973
    Abstract: There are provided compositions and methods for modulating stem cell division decisions, in particular, division symmetry. It has been demonstrated that wnt7a acts through frizzled-7 receptor expressed on the surface of adult stem cells, e.g. satellite stem cells, to activate the planar cell polarity (PCP) pathway, thereby promoting symmetrical expansion of stem cells. The compositions and methods of the invention are useful, for example, in modulating stem cell division symmetry in vitro and in vivo, in replenishing and expanding the stem cell pool, and in promoting the formation, maintenance, repair and regeneration of tissue.
    Type: Application
    Filed: August 19, 2016
    Publication date: February 16, 2017
    Inventors: Michael A. Rudnicki, Fabien Le Grand
  • Publication number: 20150125427
    Abstract: The present invention provides novel stem cells, nucleotide sequences and proteins therefrom. More specifically, the present invention provides Pax7+/Myf5? stem cells and methods for identifying and isolating them. Also provided is a MEGF10 nucleotide sequence and protein.
    Type: Application
    Filed: February 14, 2014
    Publication date: May 7, 2015
    Applicant: Ottawa Health Research Institute
    Inventors: Michael A. Rudnicki, Shihuan Kuang, Chet Holterman
  • Patent number: 9018188
    Abstract: The present invention relates to microRNAs (miRNAs) that are associated with obesity. The present invention is directed to methods, compounds, and compositions for preventing and treating obesity, as well as related diseases, using a microRNA inhibitor.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: April 28, 2015
    Assignee: Ottawa Hospital Research Institute
    Inventors: Michael A. Rudnicki, Hang Yin
  • Publication number: 20150111822
    Abstract: There are provided compositions and methods for modulating stem cell division, in particular, division symmetry. It has been demonstrated that Wnt7a polypeptide fragments promoting symmetrical expansion of stem cells. The compositions and methods of the invention are useful, for example, in modulating stem cell division symmetry in vitro, ex vivo, and in vivo, in replenishing and expanding the stem cell pool, and in promoting the formation, maintenance, repair and regeneration of tissue.
    Type: Application
    Filed: September 14, 2012
    Publication date: April 23, 2015
    Inventors: Michael A. Rudnicki, Conrad Florian Bentzinger, Radoslav Zinoviev
  • Publication number: 20140221466
    Abstract: The present invention relates to microRNAs (miRNAs) that are associated with obesity. The present invention is directed to methods, compounds, and compositions for preventing and treating obesity, as well as related diseases, using a microRNA inhibitor.
    Type: Application
    Filed: September 13, 2012
    Publication date: August 7, 2014
    Applicant: OTTAWA HOSPITAL RESEARCH INSTITUTE
    Inventors: Michael A. Rudnicki, Hang Yin
  • Patent number: 8679833
    Abstract: The present invention provides novel stem cells, nucleotide sequences and proteins therefrom. More specifically, the present invention provides Pax7+/Myf5? stem cells and methods for identifying and isolating them. Also provided is a MEGF10 nucleotide sequence and protein.
    Type: Grant
    Filed: January 13, 2012
    Date of Patent: March 25, 2014
    Assignee: Ottawa Health Research Institute
    Inventors: Michael A. Rudnicki, Shihuan Kuang, Chet Holterman
  • Publication number: 20120213744
    Abstract: There are provided compositions and methods for modulating stem cell division decisions, in particular, division symmetry. It has been demonstrated that wnt7a acts through frizzled-7 receptor expressed on the surface of adult stem cells, e.g. satellite stem cells, to activate the planar cell polarity (PCP) pathway, thereby promoting symmetrical expansion of stem cells. The compositions and methods of the invention are useful, for example, in modulating stem cell division symmetry in vitro and in vivo, in replenishing and expanding the stem cell pool, and in promoting the formation, maintenance, repair and regeneration of tissue.
    Type: Application
    Filed: April 27, 2010
    Publication date: August 23, 2012
    Applicant: OTTAWA HOSPITAL RESEARCH INSTITUTE
    Inventors: Michael A. Rudnicki, Fabien Le Grand
  • Publication number: 20120213751
    Abstract: The present invention provides novel stem cells, nucleotide sequences and proteins therefrom. More specifically, the present invention provides Pax7+/Myf5? stem cells and methods for identifying and isolating them. Also provided is a MEGF10 nucleotide sequence and protein.
    Type: Application
    Filed: January 13, 2012
    Publication date: August 23, 2012
    Applicant: OTTAWA HEALTH RESEARCH INSTITUTE
    Inventors: Michael A. Rudnicki, Shihuan Kuang, Chet Holterman
  • Patent number: 8101407
    Abstract: The present invention provides novel stem cells, nucleotide sequences and proteins therefrom. More specifically, the present invention provides Pax7+/Myf5? stem cells and methods for identifying and isolating them. Also provided is a MEGF10 nucleotide sequence and protein.
    Type: Grant
    Filed: November 22, 2006
    Date of Patent: January 24, 2012
    Assignee: Ottawa Health Research Institute
    Inventors: Michael A. Rudnicki, Shihuan Kuang, Chet Holterman
  • Publication number: 20090074730
    Abstract: The present invention provides novel stem cells, nucleotide sequences and proteins therefrom. More specifically, the present invention provides Pax7+/Myf5? stem cells and methods for identifying and isolating them. Also provided is a MEGF10 nucleotide sequence and protein.
    Type: Application
    Filed: November 22, 2006
    Publication date: March 19, 2009
    Applicant: OTTAWA HEALTH RESEARCH INSTITUTE
    Inventors: Michael A. Rudnicki, Shihuan Kuang, Chet Holterman
  • Patent number: 7384784
    Abstract: The present invention provides cells transformed with a nucleotide sequence encoding Pax7, Pax3 or both. The present invention also pertains to Pax-encoding vector that comprises a sequence encoding Pax7, Pax3 or an active variant or fragment thereof, which can be used to induce myogenic differentiation of stem cells. The present invention further pertains to methods of preparing the Pax-encoding vector. Also provided is a method of inducing myogenic differentiation in stem cells and treating a subject with the cells.
    Type: Grant
    Filed: April 30, 2004
    Date of Patent: June 10, 2008
    Assignee: Ottawa Health Research Institute
    Inventors: Michael A. Rudnicki, Patrick Seale
  • Patent number: 7045347
    Abstract: This invention provides helper-dependent adenovirus cloning vectors and helper adenoviruses, and methods for making and Using such preparations, wherein the helper adenoviruses contain recombinase target sites that are useful in reducing the level of contamination of helper virus in helper-dependent adenovirus vector preparations.
    Type: Grant
    Filed: July 26, 2002
    Date of Patent: May 16, 2006
    Assignee: Advec, Inc.
    Inventors: Frank L. Graham, Michael A. Rudnicki, Martina Anton